Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

BSX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

BSX

AI Research Report

Powered by Claude

Ready to analyze BSX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 7d (Apr 22)

Analyst Consensus

Buy
Based on 41 analysts
Period: 2026-04-01
38 Buy (93%)3 Hold (7%)0 Sell (0%)
Rating Distribution
Strong Buy
13
Buy
25
Hold
3
Sell
0
Strong Sell
0
Trend
2026-04
38/3/0
2026-03
37/3/0
2026-02
37/3/0
2026-01
36/4/0
Boston Scientific Corp

Boston Scientific Corp

Health Care·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1992-05-19
  • Yahoo·6h ago

    Citi Reiterates Buy rating for Boston Scientific (BSX)

    Boston Scientific Corp. (NYSE:BSX) is one of the 7 oversold stocks to buy with double-digit ROE growth. On April 7, Joanne Wuensch from Citi reduced the price target on Boston Scientific Corp. (NYSE:BSX) from $98 to $87 while maintaining a Buy rating on the stock. This implies an adjusted upside potential of more than 40% […]

  • Yahoo·12h ago

    EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors

    Research identifies guideline-based interpretation gaps and signal-detection issues behind non-actionable alerts and shows how an additional cloud-based AI layer can significantly reduce clinician review burden while maintaining high sensitivityCAMBRIDGE, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today revealed new research presented at the 2026 European Heart Rhythm Association Congress (EHRA) examining why

  • Finnhub·13h ago

    BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline

    Bernstein Liebhard LLP:Do you, or did you, own shares of Boston Scientific Corporation ?Did you purchase your shares between July 23, 2025 and February 3, 2026, inclusive?Did you lose money in your...

  • Yahoo·1d ago

    Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?

    Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Yahoo·4d ago

    Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System

    Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Growth Stocks to Buy for the Next Decade. Boston Scientific Corporation (NYSE:BSX) is one of the best growth stocks to buy for the next decade. On March 30, Boston Scientific received FDA 510(k) clearance for its Asurys Fluid Management System, a new technology designed to […]

  • Yahoo·4d ago

    Penumbra Sale To Boston Scientific Sparks Review Of Deal Value

    Boston Scientific has entered into a definitive agreement to acquire Penumbra (NYSE:PEN). A law firm has announced an investigation into whether the sale process and terms of the transaction are fair to Penumbra shareholders. The deal and the legal review arrive at a time when Penumbra’s share price stands at $329.52. For investors following NYSE:PEN, the agreed sale to Boston Scientific comes after a period of solid longer term returns, including 22.7% over the past year and 19.0% over...

  • Yahoo·5d ago

    Boston Scientific (BSX) Stock Slides as Market Rises: Facts to Know Before You Trade

    Boston Scientific (BSX) closed at $61.28 in the latest trading session, marking a -2.05% move from the prior day.

  • Yahoo·5d ago

    E2 raises $80M to market thrombectomy platform

    The funding round follows high-profile acquisitions by Boston Scientific and Stryker to pick up mechanical thrombectomy devices for blood clot removal.

  • View all news →
NEW YORK STOCK EXCHANGE, INC.Market closed
Boston Scientific Corp
Health Care
$63.82
$0.64 (+1.01%)
Open
$63.50
Prev close
$63.18
Day range
$63.14 – $64.48
52W range
$60.59 – $109.50
Mkt cap
$94.85B
P/E
32.9
EPS
$1.94
Beta
0.74

Fundamentals

Valuation
Market Cap
$94.85B
P/E (TTM)
32.86S&P avg ~22
P/S (TTM)
4.74S&P avg ~2.8
P/B
5.83S&P avg ~4.5
P/FCF
26.04S&P avg ~26
EPS (TTM)
$1.94
Book/sh
$16.34
Cash/sh
$1.32
Profitability
Gross Margin
69.01%avg ~45%
Operating Margin
18.00%avg ~15%
Net Margin
14.44%avg ~12%
ROE
12.57%avg ~18%
ROA
6.90%avg ~7%
ROI
8.39%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
19.88%
Rev Growth 5Y
15.16%
EPS Growth YoY
55.57%
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
1.02
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.74
52W High
$109.50
52W Low
$60.59
Avg Vol (10D)
19.09M
Avg Vol (3M)
14.35M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (41)
Price Performance
5D+2.13%
MTD+0.69%
3M-35.78%
6M-34.66%
YTD-33.74%
1Y-31.80%

Factor Grades

View details →
C+
Overall score: 57/100
C
Valuation
A-
Growth
B-
Profitability
F
Momentum
B
Financial Health
⚠️
Dilution risk detected

1 offering-related filing in the last 60 filings. Latest: 424B3 on 2026-04-01. View all →

Recent insider activity

View all →
  • 4Insider transaction
    Mar 4
  • 4Insider transaction
    Mar 4
  • 4Insider transaction
    Mar 4
  • 4Insider transaction
    Mar 4
  • 4Insider transaction
    Mar 3